Back to Results
First PageMeta Content
Proteins / Heat shock proteins / Drug discovery / Clinical research / Hsp90 inhibitors / Hsp70 / Hsp90 / Fragment-based lead discovery / Chaperone / Pharmaceutical sciences / Pharmacology / Medicine


Fragment-based Drug Discovery of the Synthetic Small Molecule HSP90 Inhibitor AT13387 A211 Christopher W. Murray, Maria G. Carr, Gianni Chessari, Miles Congreve, Joseph E. Coyle, Philip J. Day, Lynsey Fazal, Martyn Frede
Add to Reading List

Open Document

File Size: 102,80 KB

Share Result on Facebook

City

Boston / Cambridge / /

Company

Astex Therapeutics Ltd. / /

Country

United Kingdom / /

Event

FDA Phase / /

Facility

terminal HSP90 Figure / /

IndustryTerm

methoxy / chemical structure / treatment of cancer / /

MedicalCondition

melanoma / lung cancer / cancer / NSCLC / mutant B-raf melanoma / tumour / tumours / /

Person

Lynsey Fazal / Andrew J. Woodhead / Joseph E. Coyle / Christopher W. Murray / Miles Congreve / Rachel McMenamin / Brent Graham / Martyn Frederickson / Philip J. Day / Jonathan Lewis / Maria G. Carr / /

Product

AT13387 / /

Technology

pharmacokinetics / Drug Discovery / drug design / pharmacodynamics / X-ray / apoptosis / /

URL

www.astex-therapeutics.com / /

SocialTag